Lenz Therapeutics announces FDA approval of Vizz eye drop

Lenz Therapeutics (LENZ) announced the FDA approved Vizz 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. Samples are anticipated in the United States as early as October, with commercial product to be broadly available by mid-Q4. Direct-to-eye care professional sales and marketing activities to be initiated immediately.